Nanexa マネジメント

マネジメント基準チェック /44

Nanexaの CEO はDavid Westbergで、 Jan2015年に任命され、の在任期間は 9.83年です。の年間総報酬はSEK 2.85Mで、 78.4%給与と21.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.27%を直接所有しており、その価値は€ 50.25K 。経営陣と取締役会の平均在任期間はそれぞれ9.8年と3.5年です。

主要情報

David Westberg

最高経営責任者

SEK 2.8m

報酬総額

CEO給与比率	78.4%
CEO在任期間	9.8yrs
CEOの所有権	0.3%
経営陣の平均在職期間	9.8yrs
取締役会の平均在任期間	3.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Nanexa の収益と比較して、David Westberg の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-SEK 64m
Jun 30 2024	n/a	n/a	-SEK 67m
Mar 31 2024	n/a	n/a	-SEK 71m
Dec 31 2023	SEK 3m	SEK 2m	-SEK 76m
Sep 30 2023	n/a	n/a	-SEK 43m
Jun 30 2023	n/a	n/a	-SEK 49m
Mar 31 2023	n/a	n/a	-SEK 55m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 59m
Sep 30 2022	n/a	n/a	-SEK 54m
Jun 30 2022	n/a	n/a	-SEK 50m
Mar 31 2022	n/a	n/a	-SEK 42m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 36m
Sep 30 2021	n/a	n/a	-SEK 31m
Jun 30 2021	n/a	n/a	-SEK 27m
Mar 31 2021	n/a	n/a	-SEK 25m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 22m
Sep 30 2020	n/a	n/a	-SEK 19m
Jun 30 2020	n/a	n/a	-SEK 18m
Mar 31 2020	n/a	n/a	-SEK 13m
Dec 31 2019	SEK 2m	SEK 1m	-SEK 13m
Sep 30 2019	n/a	n/a	-SEK 12m
Jun 30 2019	n/a	n/a	-SEK 11m
Mar 31 2019	n/a	n/a	-SEK 12m
Dec 31 2018	SEK 2m	SEK 1m	-SEK 11m
Sep 30 2018	n/a	n/a	-SEK 9m
Jun 30 2018	n/a	n/a	-SEK 9m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 1m	SEK 1m	-SEK 8m

報酬と市場: Davidの総報酬 ($USD 258.86K ) は、 German市場 ($USD 472.15K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Davidの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

David Westberg (64 yo)

9.8yrs

在職期間

SEK 2,847,000

報酬

Mr. David Westberg has been the Chief Executive Officer at Nanexa AB (publ) since 2015. Mr. Westberg serves as an Independent Director at Lipigon Pharmaceuticals AB (publ) since 2023. Mr. Westberg has expe...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Westberg	Chief Executive Officer	9.8yrs	SEK 2.85m	0.27% € 50.3k
Marten Rooth	Co-Founder	15.8yrs	データなし	0.33% € 59.8k
Anders Johansson	Co-Founder & Head of Intellectual Property	15.8yrs	SEK 996.00k	0.30% € 55.5k
Cecilia Danckwardt-Lilliestrom	Chief Financial Officer	less than a year	データなし	データなし
Mikael Asp	Head of QA & Expert Sakkunnig	4.4yrs	データなし	0.0027% € 490.5
Joel Hellrup	Head of Pharmaceutical R&D	no data	データなし	0.0052% € 948.0

9.8yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: 40Mの経営陣は経験豊富で経験豊富です（平均在職期間は9.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Birgit Norinder	Independent Director	3.5yrs	SEK 180.00k	0.044% € 8.1k
Goran Ando	Independent Chairman of the Board	4.8yrs	SEK 260.00k	0.77% € 140.8k
Robert Gale	Member of Advisory Board - NEX-18	no data	データなし	データなし
Eva Nilsagard	Independent Director	3.5yrs	SEK 230.00k	0.13% € 24.4k
Magnus Westgren	Independent Director	9.8yrs	SEK 130.00k	0.19% € 34.4k
Axel Glasmacher	Member of Advisory Board - NEX-18 & NEX-20	no data	データなし	データなし
Richard Davis	Independent Director	2.4yrs	SEK 130.00k	データなし
Kirsten Gronbaek	Member of Advisory Board - NEX-18	no data	データなし	データなし
Uwe Platzbecker	Member of Advisory Board - NEX-18	no data	データなし	データなし
Magnus Tobiasson	Member of Advisory Board - NEX-18	no data	データなし	データなし
Jose Miguel Diaz	Member of Advisory Board - NEX-18	no data	データなし	データなし
Xavier Leleu	Member of Advisory Board - NEX-20	no data	データなし	データなし

3.5yrs

平均在職期間

69yo

平均年齢

経験豊富なボード: 40Mの取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

Nanexa マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

Less than half of directors are independent

Recent updates

Nanexa AB Announces Positive Results in the Phase I Study for NEX-22, Long Acting GLP-1, in Type 2 Diabetes

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.11 loss in 3Q 2023)

Nanexa AB (Publ) Completes Phase I Trial of NEX-22 in Type 2 Diabetes

New minor risk - Revenue size

Nanexa AB (Publ) Announces That the First Patient in the Third Dose Group with Their Long-Acting Depot Formulation of the Glp-1 Analog Liraglutide Has Been Dosed

New minor risk - Profitability

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.16 loss in 2Q 2023)

Nanexa's Phase I Trial of NEX-22 in Type 2- Diabetes Progresses with Next Dose Group According to Plan

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (Publ) Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes

New major risk - Financial position

Nanexa AB Receives Approval for NEX-22 Clinical Study

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.14 loss in 1Q 2023)

Nanexa AB (publ) Announces Approval of Clinical Trial Application for NEX-22 Study Delayed

New major risk - Shareholder dilution

Full year 2023 earnings released: kr1.09 loss per share (vs kr1.16 loss in FY 2022)

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA

Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.24 loss in 3Q 2022)

Nanexa AB Completes Clinical Phase I Study with NEX-20

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

First quarter 2023 earnings released: kr0.14 loss per share (vs kr0.24 loss in 1Q 2022)

Nanexa AB (publ) to Report Q1, 2023 Results on May 04, 2023

Full year 2022 earnings released: kr1.16 loss per share (vs kr1.01 loss in FY 2021)

Nanexa AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Nanexa Starts the Phase 1 Study of NEX-20 According to Plan

No longer forecast to breakeven

Nanexa Receives Approval to Start Clinical Trial with NEX-20

Third quarter 2022 earnings released: kr0.24 loss per share (vs kr0.18 loss in 3Q 2021)

Nanexa AB (Publ) and Vitrivax, Inc Reach Agreement in Principle

Nanexa AB (Publ) Launches NEX-22 Product Project to Address Huge Market

Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.33 loss in 2Q 2021)

Nanexa AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Nanexa AB (publ) Receives Extended GMP-Certificate for the New Pilot Plant

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

Nanexa Receives Grant from VINNOVA for Study with Monoclonal Antibodies

Forecast to breakeven in 2023

First quarter 2022 earnings released: kr0.24 loss per share (vs kr0.29 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanexa AB Announces That the Company's Preclinical Investigation

High number of new directors

Nanexa Announces Inclusion of Patients in its Phase I Study with NEX-18

Second quarter 2021 earnings released

Forecast to breakeven in 2023

High number of new directors

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.22 loss in 1Q 2020)

Nanexa Appoints Jonas Fransson as Head of Pharmaceutical Development

Full year 2020 earnings released: kr1.09 loss per share (vs kr0.88 loss in FY 2019)

Nanexa AB to Report Q1, 2021 Results on May 06, 2021

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44